1Frick MH, Haapa k, Heinonen OP, et al. The Helsinki Heart Study: primary-prevention trial with gemfibrozil in meddl- aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
2Manttari M, Elo O, Frick MH, et al. The Helsinki Heart Study:basic design and randomization procedure. Eur Heart J 1987;8:Suppl 1:1-29.
3Tenkanen L, Manttari M, Mannien V, et al. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995 ;92:1779 - 1785.
4Huttunen JK, Manninen V, Manttari M, et al. The Helsinki Heart Study: central finding and clinical implication. Ann Med 1991;23:155- 159.
5Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non- insulin dependent diabetes mellitus: United Kingdom prospective diabetes study(UKPDS:23). Br Med J 1998;316:823 - 828.
6Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200mg/day) to simvastatin(10mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91: 956 -960.
